GST-HG121 / Fujian Cosunter - LARVOL DELTA

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on GST-HG121 Tablets (clinicaltrials.gov) - P1 | N=114 | Recruiting | Sponsor: Fujian Akeylink Biotechnology Co., Ltd. | Trial completion date: Jul 2023 ➔ Mar 2024 | Trial primary completion date: Feb 2023 ➔ Dec 2023

Trial completion date • Trial primary completion date

Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on GST-HG121 Tablets (clinicaltrials.gov) - P1 | N=114 | Recruiting | Sponsor: Fujian Akeylink Biotechnology Co., Ltd.

New P1 trial

Guangshengtang: Notice of patent authorization for hepatitis B treatment innovative drug GST-HG121 in Australia and Eurasia…[Google translation] (Sina Corp) - "Guangshengtang announced that GST-HG121, an innovative hepatitis B treatment drug, has obtained a patent authorization notice in Australia and Eurasia..."

Patent • Hepatitis B • Infectious Disease

Guangshengtang (300436.SZ) obtains patent certificate or authorization notice for some innovative drugs under research [Google translation] (Sina Corp) - "Guangshengtang...has obtained a patent certificate or authorization notice for an innovative drug under development. The details are as follows:...Innovative hepatitis B treatment drug GST-HG141 obtained Eurasian patent authorization notice, hepatitis B treatment innovative drugs GST-HG131, GST-HG121 obtained U.S. and Taiwan patent certificates or authorization notices..."

Patent • Hepatitis B • Infectious Disease